Literature DB >> 9354953

Internal iliac arterial infusion chemotherapy for rabbit invasive bladder cancer.

S Hoshi1, H Mao, T Takahashi, K Suzuki, M Nose, S Orikasa.   

Abstract

BACKGROUND: Internal iliac arterial infusion (IA) chemotherapy has been used clinically for locally invasive bladder cancer, but there have been no experimental studies to actually demonstrate whether IA is more effective than intravenous infusion (i.v.) chemotherapy in this setting.
METHODS: We compared the effects of IA and i.v. using a rabbit invasive bladder cancer model. A 0.2 mL suspension containing 2 x 10(6) VX2 cancer cells was inoculated into the posterior submucosa of the bladder. Two weeks later the rabbits were divided into 3 treatment groups of 8 rabbits each: controls, a group treated with IA consisting of 10 mg/kg carboplatin and 1 mg/kg pirarubicin once a week for 3 weeks (days 14, 21, and 28), and the third treated with the same regimen intravenously.
RESULTS: All bladder tumors of the rabbits in the IA group decreased in size, and 3 of the tumors totally disappeared (37.5%). There was also no evidence of lung metastasis. All tumors in the rabbits in the i.v. treatment group increased in size (tumor volume of IA vs. i.v., P = 0.008) and 2 rabbits had lung metastases. All tumors of the control group increased in size and all rabbits had lung metastases. The concentrations of platinum and pirarubicin in the bladder tumors were significantly higher in the IA treatment group than those in the i.v. treatment group at time points from 5 to 10 minutes (P < 0.05) after drug infusion.
CONCLUSION: The antitumor effect of IA may be due to higher drug concentrations in the early stage after drug delivery, and the initial circulation of high concentrations of drugs may be the most important factor in suppressing tumor growth.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9354953     DOI: 10.1111/j.1442-2042.1997.tb00292.x

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  6 in total

1.  Intra-arterial chemotherapy combined with intravesical chemotherapy compared with intravesical BCG immunotherapy retrospectively in high-risk non-muscle-invasive bladder cancer after transurethral resection of the bladder tumor.

Authors:  Bin Huang; Gaowei Huang; Wenji Li; Lingwu Chen; Xiaopeng Mao; Junxing Chen
Journal:  J Cancer Res Clin Oncol       Date:  2020-11-22       Impact factor: 4.553

2.  The effects of intra-arterial chemotherapy on bladder preservation in patients with T1 stage bladder cancer.

Authors:  Zefu Liu; Yunlin Ye; Xiangdong Li; Shengjie Guo; Lijuan Jiang; Pei Dong; Yonghong Li; Yanxia Shi; Weijun Fan; Yun Cao; Kai Yao; Zike Qin; Hui Han; Fangjian Zhou; Zhuowei Liu
Journal:  World J Urol       Date:  2018-02-19       Impact factor: 4.226

3.  Early tumor response to intraarterial or intravenous administration of carboplatin to treat naturally occurring lower urinary tract carcinoma in dogs.

Authors:  W T N Culp; C Weisse; A C Berent; J A Reetz; E L Krick; D E Jackson; P H Kass; C A Clifford; K U Sorenmo
Journal:  J Vet Intern Med       Date:  2015-04-21       Impact factor: 3.333

4.  Application of intra-arterial chemotherapy in high-risk non-muscle invasive bladder cancer: a systematic review and meta-analysis.

Authors:  Chengyu You; Xianhui Li; Yuelin Du; Hui Wang; Xiaojun Zhang; Tangqiang Wei; Anguo Wang
Journal:  PeerJ       Date:  2021-09-28       Impact factor: 2.984

5.  Efficacy and safety of intra-arterial chemotherapy combined with intravesical chemotherapy for high-risk non-muscle invasive bladder cancer: A protocol for a systematic review and meta-analysis.

Authors:  Xing Li; Haohao Ma; Kunpeng Shu; Lingdian Wang; Degang Ding
Journal:  Medicine (Baltimore)       Date:  2019-12       Impact factor: 1.889

6.  The Efficacy of Intra-Arterial Plus Intravesical Chemotherapy Versus Intravesical Chemotherapy Alone After Bladder-Sparing Surgery in High-Risk Bladder Cancer: A Systematic Review and Meta-Analysis of Comparative Study.

Authors:  Zhongbao Zhou; Yuanshan Cui; Shuangfeng Huang; Zhipeng Chen; Yong Zhang
Journal:  Front Oncol       Date:  2021-05-27       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.